AN Venture Partners (ANV), a global biotech venture capital fund, is pleased to announce that it has been selected as a certified venture capital ("certified VC") partner for supporting biotech and pharmaceutical startups, as part of the fiscal year 2024 Strengthening Program for the Pharmaceutical Startup Ecosystem Initiative (“Strengthening Program”) being implemented by the Japan Agency for Medical Research and Development (AMED). ANV has signed a certification contract with AMED and will operate as a certified VC provider.
AMED promotes integrated research and development in the field of medicine, from basic research through to clinical trials. The Strengthening Program is an endeavor by AMED to alleviate the shortage of large-scale development funds for pharmaceutical startups. With this certification, ANV is now recognized as being able to provide hands-on development support specifically tailored to pharmaceutical startups. Moreover, if a pharmaceutical startup in which ANV has made a significant investment is selected for the AMED initiative, it will be eligible to receive AMED’s financial support for non-clinical trials, Phase 1 and Phase 2 clinical trials, or exploratory clinical trials.
Ken Horne, Managing Partner of ANV, commented, "We are extremely pleased to be recognized by AMED based on our credentials and experience. The support provided by AMED is expected to increase the number of new drug creations and elevate the entire biotech startup ecosystem in Japan. This initiative aligns with ANV’s vision of growing the biotechnology ecosystem in Japan, leveraging the more mature ecosystem in the United States and creating globally recognized biotech venture companies."
AMED’s Strengthening Program for the Pharmaceutical Startup Ecosystem
(Japanese only)
For details about the program: https://www.amed.go.jp/program/list/19/02/005.html
For information on the selected certified VCs: https://www.amed.go.jp/koubo/19/02/1902C_00045.html
About AN Venture Partners
AN Venture Partners (ANV) is a Tokyo and San Francisco-based biotech venture capital firm. ANV is dedicated to building high impact global biotech companies and specializes in sourcing scientific opportunities from Japan.